Rating : 10/10 (⭐⭐⭐⭐⭐)
🔹Since 2007, Univ.-Prof. Dr. Michael Hallek has served as the Director of the Center for Integrated Oncology (CIO) in Cologne-Bonn, and since 2019, he has expanded this role to include the CIO in Aachen, Bonn, Cologne, and Düsseldorf. He has held the C4 Professorship in Internal Medicine at the University of Cologne and has been the Director of Clinic I since 2003. From 1999 to 2003, he was a C3 Professor in Internal Medicine at the University of Munich.
🔹Prior to that, he led the Clinical Cooperation Group at the GSF (Helmholtz Institute) in Munich from 1998 to 2005, and served as a Senior Physician at the University of Munich from 1995 to 2003. Additionally, he directed the Gene Therapy Working Group at the Gene Center of the University of Munich from 1994 to 2005. His earlier training in Internal Medicine, Hematology, and Oncology was completed at the Technical University (Klinikum rechts der Isar) and the University of Munich (Klinikum Innenstadt and Großhadern) from 1985 to 2003. He also worked as a Research Associate at the Dana Farber Cancer Institute, Harvard Medical School in the USA from 1990 to 1992.
🔹In recognition of his significant contributions to the field, Prof. Hallek has received numerous awards and honors, including the Henry Kaplan Memorial Lecture at the International Conference on Malignant Lymphoma in 2021, the José Carreras Award from the European Hematology Association in 2019, and the Ham-Wasserman Lecture from the American Society of Hematology in 2018.
🔹He was also awarded the Johann-Georg-Zimmermann Medal and the Arthur Burkhardt Prize in 2017, and the German Cancer Prize in the same year. His achievements were further recognized with the Walter-Siegenthaler Medal in Gold in 2016 and the Binet-Rai Medal from the International Workshop on CLL (iwCLL) in 2013. He received the Paul-Martini Prize in 2012 and has seen the Center for Integrated Oncology repeatedly honored as an Oncology Excellence Center by an international review board of the German Cancer Aid since 2008. In 1999, he was awarded the Artur Pappenheim Prize by the German Society for Hematology and Oncology (DGHO).
🔹Since 2007: Director of the Center for Integrated Oncology (CIO) Cologne Bonn, since 2019 CIO Aachen Bonn Cologne Düsseldorf
🔹Since 2003: C4 Professorship in Internal Medicine at the University of Cologne, Director of Clinic I
🔹1999–2003: C3 Professorship in Internal Medicine at the University of Munich
🔹1998–2005: Head of the Clinical Cooperation Group at GSF (Helmholtz Institute), Munich
🔹1995–2003: Senior Physician, University of Munich
🔹1994–2005: Head of the Gene Therapy Research Group, Gene Center, University of Munich
🔹1990–1992: Research Associate, Dana-Farber Cancer Institute, Harvard Medical School, USA
🔹1985–2003: Training in Internal Medicine, Hematology, and Oncology at TU (Clinic rechts der Isar) and University of Munich (Clinic Innenstadt and Großhadern)
Memberships and Engagements
🔹2023 - 2027: Chairman of the Expert Advisory Board for Health and Care of the Federal Government
🔹Since 2022: Chairman of the Scientific Advisory Board of the Federal Medical Association
🔹Since 2022: Spokesperson for Collaborative Research Center 1530, "Enlightenment and Targeting of Pathogenic Mechanisms in B-Cell Neoplasms"
🔹Since 2022: Member of the German Council of Science and Humanities
🔹Since 2021: Member of the Scientific Advisory Board of the Robert Koch Institute
🔹Since 2021: Chairman of the Scientific Advisory Board of the German José Carreras Leukemia Foundation
🔹Since 2020: Co-Editor of the journal "Blood"
🔹Since 2019: Member of the Strategy Group "National Decade Against Cancer," Federal Ministry of Education and Research
🔹Since 2019: Member of the Supervisory Board of the University Hospital of Munich
🔹Since 2019: President of the Walter-Siegenthaler Society
🔹Since 2018: Chairman of the Scientific Committee, European School of Haematology, Paris
🔹2016-2019: Chairman and, since 2018, Managing Chairman of the German Society for Hematology and Medical Oncology
🔹Since 2014: Scientific Advisory Board of the Federal Medical Association
🔹2014–2017: Scientific Advisory Board of the American Society of Hematology, USA
🔹2014–2015: Chairman of the German Society for Internal Medicine
🔹2014: President of the German Cancer Congress 2014
🔹2013-2019: Head of Clinical Research Group 286 "DNA Damage Response in CLL" (DFG)
🔹2013–2016: Senate Commission "Fundamental Issues of Clinical Research," DFG
🔹2011-2019: Editor of the journal "Oncology Research and Treatment"
🔹Since 2011: Member of the National Academy of Sciences Leopoldina
🔹2009–2014: Spokesperson for Collaborative Research Center 832 "Tumor Microenvironment" (DFG)
🔹2000-2021: Member and, 2015-2021, Chairman of the International Working Group on CLL
🔹Since 1996: Founder and Head of the German CLL Study Group
Research Focus:
🔹Chronic Lymphocytic Leukemia (CLL) treatment in Germany
🔹Function of Chemokines and Cytokines treatment in Germany
🔹Antibodies treatment in Germany
🔹Hereditary Leukemia treatment in Germany
🔹Prof. Michael Hallek is an internist specializing in internal oncology and molecular hematology (blood diseases).
🔹The focus of his work is the development of specific molecular therapies for leukemias.
🔹He has described fundamental insights into the molecular pathogenesis and has advanced gene therapy for leukemias.
